公开(公告)号：US20240309020A1

公开(公告)日：2024-09-19

申请号：US18644056

申请日：2024-04-23

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： Xiaolun Wang ,  Aaron Craig Burns ,  James Gail Christensen ,  John Michael Ketcham ,  John David Lawson ,  Matthew Arnold Marx ,  Christopher Ronald Smith ,  Shelley Allen ,  James F. Blake ,  Mark Joseph Chicarelli ,  Joshua Ryan Dahlke ,  Donghua Dai ,  Jay Bradford Fell ,  John Peter Fischer ,  Macedonio J. Mejia ,  Brad Newhouse ,  Phong Nguyen ,  Jacob Matthew O'Leary ,  Spencer Pajk ,  Martha E. Rodriguez ,  Pavel Savechenkov ,  Tony P. Tang ,  Guy P.A. Vigers ,  Qian Zhao ,  Dean Russell Kahn ,  John Gaudino ,  Michael Christopher Hilton

IPC: C07D519/00

CPC classification number: C07D519/00

Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US20240228510A1

公开(公告)日：2024-07-11

申请号：US18286961

申请日：2022-04-14

Applicant: Mirati Therapeutics, Inc.

Inventor： Aaron Craig Burns ,  James Gail Christensen ,  John David Lawson ,  Matthew Arnold Marx ,  Christopher Ronald Smith

IPC: C07D519/00 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/438 ,  A61K31/496 ,  C07D471/04

CPC classification number: C07D519/00 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/438 ,  A61K31/496 ,  C07D471/04

Abstract: The present invention relates to compounds that inhibit KRas G12C; in particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US11964989B2

公开(公告)日：2024-04-23

申请号：US17869575

申请日：2022-07-20

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： Xiaolun Wang ,  Aaron Craig Burns ,  James Gail Christensen ,  John Michael Ketcham ,  John David Lawson ,  Matthew Arnold Marx ,  Christopher Ronald Smith ,  Shelley Allen ,  James F. Blake ,  Mark Joseph Chicarelli ,  Joshua Ryan Dahlke ,  Donghua Dai ,  Jay Bradford Fell ,  John Peter Fischer ,  Macedonio J. Mejia ,  Brad Newhouse ,  Phong Nguyen ,  Jacob Matthew O'Leary ,  Spencer Pajk ,  Martha E. Rodriguez ,  Pavel Savechenkov ,  Tony P. Tang ,  Guy P.A. Vigers ,  Qian Zhao ,  Dean Russell Kahn ,  John Gaudino ,  Michael Christopher Hilton

IPC: C07D519/00

CPC classification number: C07D519/00

Abstract: Compounds that inhibit KRas G12D. In particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I):




or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20210085683A1

公开(公告)日：2021-03-25

申请号：US17029654

申请日：2020-09-23

Applicant: Mirati Therapeutics, Inc.

Inventor： David Briere ,  James Gail Christensen ,  Pete Olson

IPC: A61K31/519 ,  C07K16/28 ,  A61P35/04

Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a an agent that blocks Programmed Death-1 receptor (PD-1) and Programmed Death Ligand-1 (PD-L1) signaling and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, kits comprising the compositions and methods of use therefor.

公开(公告)号：US10689377B2

公开(公告)日：2020-06-23

申请号：US16191190

申请日：2018-11-14

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： James F. Blake ,  Laurence E. Burgess ,  Mark Joseph Chicarelli ,  James Gail Christensen ,  Adam Cook ,  Jay Bradford Fell ,  John P. Fischer ,  Matthew Arnold Marx ,  Macedonio J. Mejia ,  Pavel Savechenkov ,  Guy P. A. Vigers ,  Christopher Ronald Smith ,  Martha E. Rodriguez

IPC: C07D471/04 ,  A61P35/00 ,  C07D491/08

Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US20190144444A1

公开(公告)日：2019-05-16

申请号：US16191190

申请日：2018-11-14

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： James F. Blake ,  Laurence E. Burgess ,  Mark Joseph Chicarelli ,  James Gail Christensen ,  Adam Cook ,  Jay Bradford Fell ,  John P. Fischer ,  Matthew Arnold Marx ,  Macedonio J. Mejia ,  Pavel Savechenkov ,  Guy P.A. Vigers ,  Christopher Ronald Smith ,  Martha E. Rodriguez

IPC: C07D471/04 ,  C07D491/08 ,  A61P35/00

Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US10125134B2

公开(公告)日：2018-11-13

申请号：US15814279

申请日：2017-11-15

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： James F. Blake ,  Laurence E. Burgess ,  Mark Joseph Chicarelli ,  James Gail Christensen ,  Jay Bradford Fell ,  John P. Fischer ,  John J. Gaudino ,  Erik James Hicken ,  Ronald Jay Hinklin ,  Matthew Randolf Lee ,  Matthew Arnold Marx ,  Macedonio J. Mejia ,  Martha E. Rodriguez ,  Pavel Savechenkov ,  Tony P. Tang ,  Guy P. A. Vigers ,  Henry J. Zecca

IPC: C07D471/04 ,  C07D519/00 ,  A61K31/519

Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US09809541B2

公开(公告)日：2017-11-07

申请号：US15343008

申请日：2016-11-03

Applicant: Mirati Therapeutics, Inc.

Inventor： Matthew Arnold Marx ,  Arkadii Vaisburg ,  James Gail Christensen ,  Robert Anthony Galemmo, Jr.

IPC: C07D211/58 ,  C07D205/04 ,  C07D211/76 ,  C07D211/88 ,  C07D221/22 ,  C07D401/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D265/10 ,  C07D213/64

CPC classification number: C07D211/58 ,  C07D205/04 ,  C07D211/76 ,  C07D211/88 ,  C07D213/64 ,  C07D221/22 ,  C07D265/10 ,  C07D401/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

公开(公告)号：US20170183308A1

公开(公告)日：2017-06-29

申请号：US15343008

申请日：2016-11-03

Applicant: Mirati Therapeutics, Inc.

Inventor： Matthew Arnold Marx ,  Arkadii Vaisburg ,  James Gail Christensen ,  Robert Anthony Galemmo, JR.

IPC: C07D211/58 ,  C07D221/22 ,  C07D401/12 ,  C07D413/14 ,  C07D417/12 ,  C07D211/76 ,  C07D211/88 ,  C07D205/04 ,  C07D413/12

CPC classification number: C07D211/58 ,  C07D205/04 ,  C07D211/76 ,  C07D211/88 ,  C07D213/64 ,  C07D221/22 ,  C07D265/10 ,  C07D401/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

公开(公告)号：US20250073241A1

公开(公告)日：2025-03-06

申请号：US18951832

申请日：2024-11-19

Applicant: MIRATI THERAPEUTICS, INC.

Inventor： Lars Daniel Engstrom ,  Peter Olson ,  James Gail Christensen

IPC: A61K31/519 ,  A61K31/506 ,  A61P35/00

Abstract: This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with CDK4/6 inhibitors.